跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,304 条关于
“BRAF Fusions”
全部
5,304
临床试验
4,616
药物
254
机构
8
资讯
426
去年
FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission
去年
FDA Approves FoundationOne CDx as Companion Diagnostic for Tovorafenib in Pediatric Low-Grade Glioma
4年前
FORE Biotherapeutics Highlights Recent Pipeline Achievements and Strategic Objectives for 2025
去年
FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials
去年
FORE Biotherapeutics Reports Durable Clinical Benefit with Plixorafenib in BRAF-Altered Thyroid Cancers
去年
Tovorafenib Shows Durable Off-Treatment Responses in Pediatric BRAF-Altered Low-Grade Glioma
去年
Targeted Therapies Transform Biliary Tract Cancer Treatment Landscape with FGFR2 Inhibitors Leading Clinical Advances
5个月前
FORE Biotherapeutics Receives First-Ever Breakthrough Therapy Designation for High-Grade Glioma Targeted Therapy
去年
FDA Approvals in 2024: Novel Therapies for MASH, WHIM Syndrome, Pediatric Glioma, MDS, and Bladder Cancer
去年
Molecular Testing Reshapes Treatment Landscape in Advanced Pancreatic Cancer, Highlighting Promise of RAS Inhibitors
第 1 页,共 43 页
上一页
下一页